| abstract |
FIELD: chemistry. n SUBSTANCE: invention relates to novel pyrrolopyrimidines of general formula (I) or pharmaceutically acceptable salts thereof, having JANUS: JAK2, JAK3 protein kinase, protein kinase A (PKA), serine/threonine protein kinase ROCK inhibiting properties. The compounds can be used to treat such diseases as allergy, asthma, atopic dermatitis and others. In structural formula (I): R 1 denotes H; R 2 denotes H; Z 1 denotes C 1-6 aliphatic group or C 5-7 cycloaliphatic group, optionally substituted with 0-1 groups J z ; if the bond between Z 1 and C is a double bond, then Z 1 can also denote =O or =C(R) 2 ; Z 2 denotes H; or C 1-10 halogenalkyl, -(V n )-CN, (V n )-(heterocyclyl), where the heterocyclyl is a 6-member ring containing a nitrogen atom or two oxygen atoms as heteroatoms, -(V n )-(phenyl) or -(V n )-(C 3-10 cycloaliphatic group), optionally substituted with 0-1 groups J z ; or Z 1 and Z 2 together with the carbon atom with which they are bonded form a ring Q; Z 3 denotes H or C 1-6 alkyl, optionally substituted with 0-1 groups J z ; or Z 1 , Z 2 and Z 3 together with the carbon atom with which they are bonded form a 6-8-member saturated bicyclic ring Q; where if the bond between Z 1 and C is a triple bond, then Z 2 and Z 3 are absent; if the bond between Z 1 and C is a double or triple bond, then Z 3 is absent or Z 2 and Z 3 are absent; Q denotes a 3-8-member saturated or partially saturated monocyclic ring containing 0-2 heteroatoms selected from nitrogen, oxygen or sulphur, where said Q is optionally and independently condensed with Q 1 ; where said Q is optionally substituted with 0-4 groups J Q , where said Q is optionally substituted with 0-4 groups J Q . Values of other radicals are given in the claim. n EFFECT: high efficiency of using the compositions. n 35 cl, 5 dwg, 5 tbl, 14 ex |